Chinese pharmaceutical company
Appears in 3 stories
Developer of olatorepatide; NDA under review in China for weight management
Hansoh Pharma presented full Phase III results for olatorepatide at the European Association for the Study of Diabetes meeting in Milan on October 2. Overweight and obese patients on the highest 15 mg dose lost 19.3% of their body weight on average by week 48, and the weight-loss curve had not flattened.
Updated Oct 2
Developer of HS-20093, the lead B7-H3 ADC in China
On September 2, 2026, China's drug regulator accepted the first marketing application for Hansoh Pharmaceutical's HS-20093, a targeted cancer drug built around the protein B7-H3. The filing covers small cell lung cancer after prior platinum-based chemotherapy and follows a July phase 3 win: the ARTEMIS-008 trial met its primary endpoint of overall survival, making HS-20093 the first B7-H3-directed antibody-drug conjugate to show a survival benefit in any tumor type.
Updated Sep 13
Licensor of AVR-001 and co-lead investor in the financing
The team that built Akero Therapeutics and sold it to Novo Nordisk for up to $5.2 billion has a second act. On Tuesday, their new startup, Avere Therapeutics, agreed to merge with struggling public biotech NextCure and raised $320 million to fund it.
Updated Jul 14
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
